Product Description
For excessive dermal/keloid scarring and fibrotic disorders
Mechanisms of Action: HSP20 Mimetic
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Capstone
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Keloid|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00811577 |
OL-ASCAR-03 | P2 |
Completed |
Other |
2010-12-01 |
2019-03-18 |
Treatments |
|
NCT00892723 |
OL-ASCAR-05 | P2 |
Completed |
Keloid |
2010-09-01 |
2019-03-18 |
Treatments |
|
NCT00825916 |
OL-ASCAR-04 | P2 |
Completed |
Keloid |
2010-07-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|